# Junta clínica — PT-pseudo_d38917f87b35 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d38917f87b35",
  "pid": "PT-pseudo_d38917f87b35",
  "task": 1,
  "psa": 28.3,
  "age": 61,
  "months": 2,
  "pirads": "5",
  "psad": 0.4,
  "psav": -0.78,
  "psap": 25.3,
  "vol": 70.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.8709831,
  "medhx": "Type 2 diabetes, Hypercholesterolaemia",
  "meds": "empagliflozin, simvastatin, rosuvastatin",
  "notes": "PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.",
  "pmhx": [
    "Type 2 diabetes",
    "Hypercholesterolaemia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "99 kg",
    "height": "177 cm",
    "bmi": "31.6",
    "bp": "126/68 mmHg",
    "hr": "67 bpm",
    "smoking": "Ex-smoker (23 pack-yr, quit 2015)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "11 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review."
    },
    {
      "s": "History",
      "t": "A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable."
    }
  ],
  "occupation": "retired firefighter",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions"
  ],
  "alcohol": "12 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 19/35 (moderate LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d38917f87b35
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 28.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: -0.78 ng/mL/yr
  - Prior PSA: 25.3 ng/mL
  - Prostate volume: 70.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8709831 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia
  - Current medication: empagliflozin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.

Vitals: weight 99 kg, height 177 cm, BMI 31.6, BP 126/68 mmHg, HR 67 bpm. Smoking: Ex-smoker (23 pack-yr, quit 2015).

Chief complaint: Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review.

History: A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine.

Physical examination: DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable.

Patient info: retired firefighter; Widowed; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 12 units / week; exercise Running 3x/week, 5 km; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.34
  uncertainty  +/- 0.14 epistemic (95% band 0.07-0.61); among patients I cannot tell apart the outcome was 0.93 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 28.3, PSAD 0.4, age 61, DRE Nodus -> DEFER (clear). He wrote: "Highrisk disease in young patient. Should be treated, not get another biopsy."
  2. distance 1.30: PI-RADS 5, PSA 10.92, PSAD 0.26, age 61, DRE Nodus -> DEFER (clear). He wrote: "Advocate for curative treatment while unfavorable intermediate risk pc in young patient without significant comorbidity. IF he is cautious toward curative treatment, rep…"
  3. distance 1.76: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"

PRECEDENT: DEFER. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: pirads=important, age=important, bx=important, fh=noted, comorbidity=noted, psa=important, dre=important, psad=important, vol=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is contradicted by the guideline's emphasis on MRI findings mandating repeat biopsy for histological progression. Expert 4's focus on the documented plan of opening specific documents does not address the guideline's requirement for specific MRI findings to dictate the next step.

WHAT WE STILL NEED
The guideline requires information on the MRI findings to determine if a repeat biopsy is mandated.
The prior biopsy status is documented as "Positive (ISUP GG5 disease)" in the notes, which is a finding that the guideline makes decisive.
The PI-RADS score of 5 is a value already on the panel, which the guideline makes decisive.
The PSA velocity of -0.78 ng/mL/yr is a value already on the table, which the guideline makes decisive.
The prostate volume of 70.0 mL is a value already on the table, which the guideline makes decisive.
The prior biopsy status is documented as "Positive (ISUP GG5 disease)" in the notes, which is a finding that the guideline makes decisive.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 5 finding and the prior positive biopsy status mandate a repeat biopsy according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the specific finding regarding the lesion size and zone?
  psa_trend (get_psa_trend) -> What is the PSA trend information?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy grade and surveillance plan?
  laboratory_results (get_lab_results) -> What are the full laboratory results, specifically the free-PSA fraction and renal function?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the specific finding regarding the lesion size and zone from the radiology_report?
  Q2. What is the PSA trend information from the psa_trend?
  Q3. What is the management context regarding the prior biopsy grade and surveillance plan from the previous_notes?
  Q4. What are the full laboratory results, specifically the free-PSA fraction and renal function?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The specific finding regarding the lesion size and zone from the radiology_report is: "A discrete abnormality localizes to the left peripheral zone, spanning the base through mid-gland, measuring roughly 28 mm longest diameter. T2 sequences highlight pronounced hypointensity within this focus. Diffusion-weighted techniques demonstrate marked restriction, mirrored by low apparent diffusion coefficient values."

psa_trend
The PSA trend information from the psa_trend is: [{"date": "Jul 2023", "val": 1.3}, {"date": "Dec 2023", "val": 19.1}, {"date": "Apr 2024", "val": 9.0}, {"date": "Aug 2024", "val": 9.7}, {"date": "Jan 2025", "val": 28.3}].

previous_notes
The management context regarding the prior biopsy grade and surveillance plan from the previous_notes is: "An April 2024 PSA draw returned 23.1 ng/mL, continuing the rising trend established since the initial biopsy confirmed a Positive result earlier in the calendar year. Clinical tracking focused on lower urinary tract symptom progression and overall health status."

laboratory_results
The full laboratory results, specifically the free-PSA fraction and renal function from the laboratory_results are: PSA: "28.3 ng/mL" on "02 Dec 2024" with flag "H"; Free PSA: "3.22 ng/mL" on "02 Dec 2024" with flag ""; %Free PSA: "11%" on "02 Dec 2024" with flag "L"; Creatinine: "90 umol/L" on "02 Dec 2024" with flag ""; eGFR: ">60 mL/min/1.73m2" on "02 Dec 2024" with flag ">60 mL/min/1.73m2".

WHAT I DID NOT OPEN
family-history anamnesis, because the information was not explicitly requested by the moderator and is not critical for the immediate decision based on the opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now:
PI-RADS score of 5 from the radiology_report.
Prior biopsy status of "Positive (ISUP GG5 disease)" from the previous_notes.

AGAINST sampling this patient now:
PSA velocity of -0.78 ng/mL/yr from the panel.

WHERE THIS LEANS
The combination of a PI-RADS 5 finding and a prior positive biopsy strongly suggests a need for further histological confirmation, aligning with the EAU guideline emphasis on MRI findings.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 28.30 ng/mL over 5 points spanning 18 months; velocity +12.71 ng/mL per year; doubling time about 5 months.
PROJECTION at 6 months: 83.4 ng/mL, conformal 95% band 23.9-290.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.27
  uncertainty  +/- 0.13 epistemic (95% band 0.02-0.52), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.34  ('supports' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.27  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (identical panel in the series)
  EXPERT-COHORT      DEFER  (rule psa_ge_20)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: NO BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: pirads=important, age=important, bx=important, fh=noted, comorbidity=noted, psa=important, dre=important, psad=important, vol=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to have addressed all the moderator's questions, as the registrar reported findings for the radiology report, PSA trend, previous notes, and laboratory results.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with NO BIOPSY based on an identical precedent in the labelled series, which aligns with the panel's final answer.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Answered by the registrar's report: "A discrete abnormality localizes to the left peripheral zone, spanning the base through mid-gland, measuring roughly 28 mm longest diameter. T2 sequences highlight pronounced hypointensity within this focus. Diffusion-weighted techniques demonstrate marked restriction, mirrored by low apparent diffusion coefficient values."
Q2. Answered by the registrar's trend data: The PSA trend shows a rising trajectory, with the latest value being 28.3 ng/mL in January 2025.
Q3. Answered by the registrar's notes: The management context is that an April 2024 PSA draw returned 23.1 ng/mL, continuing the rising trend established since the initial biopsy confirmed a Positive result earlier in the calendar year.
Q4. Answered by the registrar's lab results: The free-PSA fraction was 11% on December 2nd, 2024, and the eGFR was >60 mL/min/1.73m2.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 5 from the radiology report and the documented prior positive biopsy status are the most critical variables, as they directly relate to the EAU guideline emphasis on MRI findings mandating further histological confirmation.

MY SUGGESTION TO THE CHAIR
Given that the opened documents confirm a high-risk MRI finding (PI-RADS 5) and a prior positive biopsy, which aligns with the EAU guideline's emphasis on MRI findings, I suggest proceeding with a biopsy to confirm histological progression, despite the panel's decision.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The panel protocol concluded with no biopsy based on an identical precedent in the labelled series, which is a strong factor. However, the Verifier suggested biopsy, driven by the PI-RADS 5 finding and the prior positive biopsy status, which aligns with EAU guidelines. Since no retrieved finding explicitly overturns the panel's decision, I defer to the established protocol, acknowledging the conflicting expert input.

What carried weight: pirads=important, age=important, bx=important, comorbidity=noted, psa=important, dre=important, psad=important, vol=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
